| HOME >> BIOLOGY >> TECHNOLOGY |
DENVER and GOLDEN, Colo., April 2, 2008 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today that it will exhibit for the first time at the 14th Annual Conference and Exhibition of the Society for Biomolecular Sciences (SBS) in St. Louis, April 6 - 10, 2008.
"We are extremely pleased to support the advancement of the science of drug discovery by exhibiting at the SBS meeting, especially as it is a non-profit forum. This is our first in what I foresee as a multiple year commitment to supporting this cutting edge area of basic and applied pharmaceutical research," said Ken Wilczek, President of ABR. "It is truly a privilege to be involved with these top-level, dedicated institutions and talented individuals in the furtherance of innovative drug discovery research that could lead to potentially life-saving therapies," continued Mr. Wilczek. ABR-Affinity BioReagents' high quality portfolio of monoclonal and polyclonal antibodies, recombinant proteins, siRNA and custom antibody and peptide production services are already in use by every major research institution, government agency, university, and pharmaceutical company in the world today.
"Feedback from leading researchers in the areas of cancer biology and disease research, especially arthritis and inflammation, is invaluable to us in determining strategic direction. The international character of this audience will enable ABR to collaborate on a meaningful level with the most influential scientists in the world," noted Mr. Wilczek. ABR-Affinity BioReagents will be located at booth #220.
About ABR-Affinity BioReagents
Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand(R).
With more than 35,000 antibodie
'/>"/>
| SOURCE ABR-Affinity BioReagents Copyright©2008 PR Newswire. All rights reserved |